A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Clinical trial NCT07361497 · RECRUITING
Trial details
- NCT number
- NCT07361497
- Sponsor
- Bristol-Myers Squibb
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-16
- Primary completion
- 2030-09-18
- Enrollment
- 850
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.